Division of Endocrinology and Metabolism, Welch Center for Prevention, Epidemiology, and Clinical Research Johns Hopkins University School of Medicine, 2024 E Monument Street, Suite 2-600, Baltimore, MD 21287, USA.
Am J Cardiol. 2011 Aug 2;108(3 Suppl):59B-67B. doi: 10.1016/j.amjcard.2011.03.017.
Type 2 diabetes mellitus (DM) affects an estimated 25.8 million people in the United States and is the 7th leading cause of death. While effective therapy can prevent or delay the complications that are associated with diabetes, according to the Center for Disease Control, 35% of Americans with DM are undiagnosed, and another 79 million Americans have blood glucose levels that greatly increase their risk of developing DM in the next several years. One of the Healthy People 2020 goals is to reduce the disease and economic burden of DM and improve the quality of life for all persons who have, or are at risk for, DM. Achieving this goal requires a concentrated focus on improving the management of diabetes and in targeting prevention of macrovascular complications. This article reviews established and emerging therapeutic approaches for managing DM and prevention of macrovascular complications.
2 型糖尿病（DM）在美国影响约 2580 万人，是第 7 大死亡原因。虽然有效的治疗可以预防或延缓与糖尿病相关的并发症，但据疾病控制中心称，35%的美国 DM 患者未被诊断，另有 7900 万美国人的血糖水平大大增加了他们在未来几年患 DM 的风险。《2020 年健康人》的目标之一是降低糖尿病的疾病和经济负担，并改善所有患有或有患糖尿病风险的人的生活质量。要实现这一目标，就需要集中精力改善糖尿病的管理，并针对预防大血管并发症。本文回顾了管理 DM 和预防大血管并发症的既定和新兴治疗方法。
